EIKN (Eikon Therapeutics) DeferredTaxAndRevenue: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EIKN Eikon Therapeutics Inc EIKN
12 GF Score
Price $10.93
View Full Analysis

What is Eikon Therapeutics DeferredTaxAndRevenue?

Eikon Therapeutics EIKN -3.78% 12 DeferredTaxAndRevenue is $0.00 Mil as of Jun. 2026. GuruFocus rates EIKN with a GF Score™ of 12/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Eikon Therapeutics's current deferred tax and revenue for the quarter that ended in Jun. 2026 was $0.00 Mil.

Eikon Therapeutics DeferredTaxAndRevenue Related Terms

Eikon Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Eikon Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics DeferredTaxAndRevenue Chart

Eikon Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
DeferredTaxAndRevenue
0.00 0.00 0.00

Eikon Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EIKN
12GF Score
Eikon Therapeutics Inc EIKN
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Eikon Therapeutics (EIKN) has a DeferredTaxAndRevenue of $0.00 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Eikon Therapeutics.
Is Eikon Therapeutics' DeferredTaxAndRevenue too high?
Eikon Therapeutics' current DeferredTaxAndRevenue is $0.00 Mil. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' DeferredTaxAndRevenue compare to SPRY and ARVN?
Eikon Therapeutics' DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Eikon Therapeutics. Eikon Therapeutics's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current DeferredTaxAndRevenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eikon Therapeutics Business Description

Address 230 Harriet Tubman Way, Millbrae, CA, USA, 94030
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score

Get the complete analysis for EIKN

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.93
Price